Nairobi-Kenya: GlaxoSmithKline (GSK) announced the third call for proposals as part of the Africa non-communicable diseases (NCD) Open Lab this week, strengthening the company’s commitment to much-needed scientific research into NCDs.
The Africa NCD Open Lab is part of a series of investments GSK is making across Sub-Saharan Africa. The Open Lab, launched in 2014, aims to work in partnership with African researchers and academic groups to conduct research into NCDs such as cancer, diabetes, cardiovascular disease and chronic respiratory diseases.